自身免疫性疾病患者妊娠期靶向合成改善病情抗风湿药的妊娠结局:范围综述
本范围综述检索Embase、MEDLINE和CENTRAL数据库至2023年11月,纳入8项研究(9例病例报告、1项病例系列、4项横断面研究、1项队列研究),涉及溃疡性结肠炎、类风湿关节炎和银屑病患者,样本量1至116例妊娠或子代。托法替布相关研究6项,巴瑞替尼1项,乌帕替尼1项,阿普米司特无研究。作者结论为样本量小、研究数量有限且多为描述性,证据缺口妨碍了围产期用药的知情决策。
要点
- 纳入8项研究,样本量1至116例妊娠或子代,6项涉及托法替布,1项巴瑞替尼,1项乌帕替尼,无阿普米司特研究。
- 最常报告的胎儿/新生儿结局为先天性异常(n=4)、早产(n=4),胎儿/新生儿-母亲结局为自然流产(n=4)。
- 仅1项研究报告母亲结局为剖宫产分娩。
核心结论
- 作者结论为当前关于靶向合成改善病情抗风湿药围产期使用的证据样本量小、研究数量有限且多为描述性。
- 作者指出证据缺口妨碍了提供者和患者在考虑围产期使用靶向合成改善病情抗风湿药时做出知情决策。
研究设计与样本
- 研究设计为范围综述,检索Embase、MEDLINE和CENTRAL数据库,检索时间为2023年11月。
- 纳入标准为考察慢性自身免疫性疾病中靶向合成改善病情抗风湿药暴露的研究,包括母亲妊娠期、父亲孕前和/或胎儿/新生儿在子宫内暴露。
- 共筛选6712项研究,最终纳入8项研究,包括9例病例报告、1项病例系列、4项横断面研究和1项队列研究。
- 纳入研究涉及溃疡性结肠炎、类风湿关节炎和银屑病患者,样本量范围为1至116例妊娠或子代。
- 8项研究中6项涉及托法替布,1项涉及巴瑞替尼,1项涉及乌帕替尼,无阿普米司特相关研究。
主要发现
- 共提取19项胎儿/新生儿结局、6项胎儿/新生儿-母亲结局和3项母亲结局。
- 最常报告的胎儿/新生儿结局为先天性异常(n=4)和早产(n=4)。
- 最常报告的胎儿/新生儿-母亲结局为自然流产(n=4)。
- 仅1项研究报告母亲结局为剖宫产分娩。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出样本量小。
- 作者指出研究数量有限。
- 作者指出纳入研究多为描述性。
- 作者指出证据缺口妨碍了提供者和患者在考虑围产期使用靶向合成改善病情抗风湿药时做出知情决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy. We conducted a scoping review to synthesize the current evidence on the impacts of tsDMARDs on pregnancy outcomes. METHODS: We searched the Embase, MEDLINE, and CENTRAL databases in November 2023. We included studies that examined tsDMARD exposure for chronic autoimmune disease(s), particularly in mothers during pregnancy, fathers before conception, and/or fetuses/neonates in utero. We extracted data on sample size, study design, tsDMARD exposure (dose and duration), and reproductive health outcomes. RESULTS: Of 6,712 studies screened, eight were included, namely nine case reports, one case series, four cross-sectional studies, and one cohort study among patients with ulcerative colitis, rheumatoid arthritis, and psoriasis. Sample sizes ranged from 1 to 116 pregnancies or offspring, with six studies on tofacitinib, one on baricitinib, one on upadacitinib, and no studies on apremilast. Overall, 19 fetal/neonatal outcomes, six fetal/neonatal-maternal outcomes, and three maternal outcomes were extracted. The most frequently reported fetal/neonatal outcomes were congenital anomaly (n = 4), preterm birth (n = 4), and the fetal/neonatal-maternal outcome of spontaneous abortion (n = 4). Only one study reported on the maternal outcome of delivery via Cesarean section. CONCLUSION: Our scoping review of evidence to date on the perinatal use of tsDMARDs reveal small sample sizes and a limited number of studies, all largely descriptive in nature. Findings highlight evidence gaps that preclude providers and patients from making informed decisions when considering the perinatal use of tsDMARDs.
引用
- Cheng V, Amiri N, Cheng V, et al. Pregnancy Outcomes of Targeted Synthetic Disease-Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review. Arthritis Care Res (Hoboken). 2025. PMID: 39895048. doi:10.1002/acr.25502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。